Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Zinan Feng
Institutions:
Nanfang Hospital,
Southern Medical University
Observed institutions:
Sichuan University,
Nanfang Hospital,
Sichuan Center for Disease Control and Prevention,
Southern Medical University
ORCID:
0000-0001-9690-9160
Observed ORCID:
0000-0001-9690-9160
OpenAlex ID:
A5045018415
The community structure of human cellular signaling network
2007
·
Yuanbo Diao
, Menglong Li
, et al.
·
Journal of Theoretical Biology
·
51
MWCNTs-solid phase extraction combined with ultra-high performance liquid chromatography-tandem mass spectrometry for the determination of eleven organophosphorus pesticides in river water
2018
·
Lin Liu
, Yang Jiang
, et al.
·
International Journal of Environmental & Analytical Chemistry
·
11
Get ready for the CRISPR/Cas system: A beginner's guide to the engineering and design of guide RNAs
2021
·
Shufeng Ma
, Jie Lv
, et al.
·
The Journal of Gene Medicine
·
6
A prophylactic tyrosine kinase inhibitor strategy based on measurable residual disease pre‐transplantation for Ph + acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: A prospective multicenter cohort study
2024
·
Hui Liu
, Hui Xu
, et al.
·
American Journal of Hematology
·
4
Intensified conditioning containing decitabine versus standard myeloablative conditioning for adult patients with KMT2A-rearranged leukemia: a multicenter retrospective study
2024
·
Zhongli Hu
, Zinan Feng
, et al.
·
BMC Medicine
·
3
PDF
Autologous transplant versus matched sibling donor transplant in intermediate-risk AML in CR1 with no detectable MRD: a biological assignment comparative study
2026
·
Sijian Yu
, Hui Liu
, et al.
·
Experimental Hematology and Oncology
High-dose cytarabine with idarubicin consolidation for acute myeloid leukemia in first complete remission: a randomized controlled trial
2025
·
Yu Zhang
, Zinan Feng
, et al.
·
Leukemia
High-Dose Cytarabine with Idarubicin Versus High-Dose Cytarabine within First Consolidation for Acute Myeloid Leukemia in First Complete Remission: An Open-Label, Multicenter, Randomized, Phase 3 Trial
2024
·
Zinan Feng
, Yu Zhang
, et al.
·
Blood
Dynamic MRD-Directed Post-Remission Treatment in Patients with Intermediate-Risk Acute Myeloid Leukemia in First Remission: Prospective Validation in a Multicentre Cohort
2024
·
Sijian Yu
, Yu Zhang
, et al.
·
SSRN Electronic Journal
Show more works
View as search
Works count:
9
Citation count:
75
H-index:
4
I10-index:
2
Year
Topic
Type
